Helomics Named Tech 50 Finalist By Pittsburgh Technology Council

PITTSBURGH--(BUSINESS WIRE)--Helomics^® Corporation, a privately-held personalized healthcare company that provides comprehensive tumor profiling products and services based on both live and fixed cell assays, announced today that the Company is a finalist in the Pittsburgh Technology Council’s annual Tech 50 Awards. Helomics was selected as a finalist in the Innovator of the Year – Life Sciences category.

“We’re honored to be recognized as one of Pittsburgh’s leading companies”

The Pittsburgh Technology Council’s annual Tech 50 Awards recognizes southwestern Pennsylvania’s most successful, innovative, and thought-leading technology companies, which has become the backbone of Pittsburgh’s economy. The awards represent transformative technology centers of excellence within companies at all stages of growth. To identify the finalists, the Pittsburgh Technology Council canvasses the region for the most distinguished public and private technology-oriented companies that demonstrate the strongest growth and advancement in product or sales success, financial strength, corporate citizenship, job growth and retention and innovative product or technology.

“We’re honored to be recognized as one of Pittsburgh’s leading companies,” said Neil Campbell, President and CEO of Helomics. “At Helomics we have a dedicated team that takes pride in using novel technology to analyze tumor samples and provide cancer patients and their oncologists with personalized treatment paths. We truly believe personalized medicine can make a difference in the lives of people with cancer and are thrilled that the Pittsburgh Technology Council believes in our vision.”

About Helomics^® Corporation, Inc.

Helomics^® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and important factors that could cause actual results to differ materially from those communicated in any forward-looking statements information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.